Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.

Slides:

Advertisements

Similar presentations

Supporting the Rationale for the Use of Dapagliflozin as an Add-on to Poorly Controlled Patients on Saxagliptin and Metformin Zachary Bloomgarden, MD Clinical.

Advertisements

Case-Based Examination of Treatment Options in Type 2 Diabetes Management.

Taieb V, et al. Value Health Nov;18(7):A598.

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

ICD-10 and Clinical Documentation

An Endocrinology Clinic in Dyslipidemia

New Data on the Safety of SGLT2 Inhibitors

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

Updates on Emerging GLP-1 Receptor Agonists

Updates on CVOT Data and Clinical Comparisons That Matter

SGLT2 Inhibitors and Their Clinical Impact:

Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?

Patient Case Discussions in T2D: What Intensification Plan Is Best?

Updates on Outcomes for Novel T2D Therapies

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Figure 4 Effect of dapagliflozin on HbA1c and body weight

SGLT2 Inhibitors in Phase 3 Trials

Updates Abound.

SGLT2 Inhibitors in the Modern Era: Why and Where?

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

How Effective Is Fixed-Dose Combination Therapy in T2D and Where Does It Fit?

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

GLP-1 Receptor Agonists: How Early Is Appropriate?

A Deep Dive Into CVOTs.

Translating Atopic Dermatitis

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Next-Gen Psoriasis Therapies:

Case Study Role of DPP-4 Inhibitors

2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Early and Intensive T2D Management:

Breaking Down the CVOTs

EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Oral Anticoagulation in AF

Antihyperglycemic therapy in type 2 diabetes: general recommendations

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Extraordinary Cases of VTE Prevention in Patients With Cancer

Learning Objectives Metabolic Abnormalities Associated With T2D.

Novel Approaches to T1D Management

Antihyperglycemic Therapy

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Pivotal Data Highlights on Myeloproliferative Neoplasms Myelofibrosis

A Time for Change for Managing Patients With VTE Who Have Cancer

CAD and HF Often Coexist

The Role of the Kidney in Glucose Control

Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.

Oral Combination Therapy for T2D

Insulin in Diabetes Management: Effective Patient Selection Is Key

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

Add-On Therapy to Insulin in T1DM Management

Patient Selection for Modern T2D Agents

Approximate Dose Equivalency of Statin LDL-C Efficacy.

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Improving Overall Health

DECLARE-TIMI 58.

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

AMD Therapy: Where Are We Now and Where Are We Going?

Emerging Combination Injectable Therapy A New Era in Diabetes Care

PAH Pathways: What Do the Data Tell Us?”

Achieving Lipid Targets With PCSK9 Inhibition

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

What's New in Oral Combination Therapy for Type 2 Diabetes?

Emerging Advances in Reducing Renal Complications of T2D

The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum

The Power of As-Treated Analyses

Presentation transcript:

Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin

Program Goals

Canagliflozin Use in Older Patients With Type 2 Diabetes: Safety and Efficacy

Inhibiting SGLT-2 Receptors: Clinical Implications

Attainment of Diabetes-related Goals With Canagliflozin

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)